

Title:
Why anal cytology is not enough in a dysplasia screening program

Authors:
Marco Silva, Rosa Coelho, Guilherme Macedo

DOI: 10.17235/reed.2018.5678/2018

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:
Silva Marco, Coelho Rosa, Macedo Guilherme. Why anal cytology is not enough in a dysplasia screening program. Rev Esp Enferm Dig 2018. doi: 10.17235/reed.2018.5678/2018.

Enero 2017 • Volumen 109 • Número 1 • Páginas 1-86

Revista Española de Enfermedades Digestivas
THE SPANISH JOURNAL OF GASTROENTEROLOGY

Acceso al texto completo en: www.reed.es o www.sped.es

Factor de impacto 100 (ISI) JCR: 1.455 (2016)
SCR: 0.34 (2016)

ORGANO OFICIAL DE:
SOCIEDAD ESPAÑOLA DE PATOLOGÍA DIGESTIVA, SOCIEDAD ESPAÑOLA DE ENDOSCOPIA DIGESTIVA Y ASOCIACIÓN ESPAÑOLA DE ECOGRAFÍA DIGESTIVA

SEPO

Editorial Colitis diverticular bleeding. Have we identified the risk factors for massive bleeding yet? J. W. Bercian Valencia	Lesión de Bowdman: diagnóstico por gastroscopia R. Barrio Guea, N. N. Barrio Irujo, M. Paz Nová y J. E. Domínguez Muñoz	65
Trabajos Originales Risk factors for severity and recurrence of colorectal diverticular bleeding N. Aragón, P. Cabero, A. Arduas, M. Escobar and N. Guzmán	Notas Clínicas Colitis crónica in adults: a case report and review of the literature focusing in the presentation of subacute syndrome M. de Alaveda-Nemón, V. L. Barrio-Cabral and S. Latorre	67
Microsporidian and inflammatory bowel disease: the other diagnosis J. Barrio, A. Aguiló, S. López-Casas, J. Cuervo, M. Acuña-Barca, M. Hernández-Serra, C. García, M. de la Cruz, D. Barrio and A. López-García	Herangopitosis: tumor patético. Una localización infrecuente de tumor intestinal I. Alonso Abad, J. M. García-Cerón, L. Aguirre-Díaz, A. M. Quintana-Berco y A. Colla-Morero	69
Influence of sustained blood response on the regression of fibrosis and portal hypertension in cirrhotic (HCV) patients treated with antiviral therapy A. Barrio, J. Cabero, M. J. López-Alca, I. López, M. T. Arce, A. Galván, F. Castiella, E. Fabregat and J. Crespo	Hemólisis por eritropoiesis supresiva intracraneal C. Pérez-Carpas, A. Escobedo-Sánchez, M. A. Paredes-Capó, J. Arangul-Arribas y C. García-Delgado	70
Malnutrition risk questionnaire combined with body composition measurement in malnutrition screening in inflammatory bowel disease A. A. Cortés, A. Muñoz, Z. Pili, I. Pall and P. Malvar	Endoscópico removal of intubated large nasogastric tubes: a case report M. Ochoaizabal and C. Soler-Munoz	73
A survey-based analysis on endoscopic quality indicators compliance among Spanish endoscopists I. Fernández-Cruz, F. Argüelles, P. Alonso, J. Salas and S. Soriano	Microscopio electrónico en un caso de absceso de abdomen agudo A. Tapia-Palacio, M. R. Ramos-Vázquez, J. C. Cordero-Ramos, J. Cornejo-Larrea and L. Carballo-Pérez	76
Revisión Endoscopic resection of colorectal polyps in patients on antiplatelet therapy: an evidence-based guideline for clinicians G. Piana, M. Sostero-Salín, C. Salinas, F. Day and M. J. Cuervo	Cartas al Editor Neoplasia neuroendocrina intestinal, un tumor poco habitual M. de Barrio Nová, J. Barrio Fernández y M. N. Barrio Rodríguez	79
Indicadores en Patología Digestiva Trastorno de la artéria mesentérica superior: una causa infrecuente de obstrucción intestinal J. Sempere Jaque, P. Albaladejo-Serra y J. C. García-Pérez	Prevalencia intestinal de infección por helicobacter pylori gastritis asociada a consumo de Bisacodil, patología infrecuente y poco conocida Y. Pardo-Vargas, D. M. Aguirre y L. A. Alvarado	80
Neumotórax espontáneo intestinal A. F. Romero-Muñoz y R. Barrio-Zelga	Perforación múltiple de divertículos de intestino delgado en paciente con síndrome de Ulceras Duodenales R. Fernández-Cruz, A. Barrio-Cabero y E. Palencia López	83
Síndrome de Miller a cinco años de diagnóstico C. Ochoa-Sandoval, C. C. Hernández-Segura, J. Pineda-Rodríguez y A. N. González-Fernández	Altoprecia analítica como manifestación paraneoplásica de un adenoma actínico gástrico J. Barrio Nová, F. Fernández-Serrano y J. de la Fuente-Aguado	83
Endoscopic retrieval of trichobezoars in a schizophrenic patient J. L. Barrio-Hernández, M. E. Torres-Castro and M. Torres-Rodríguez	Revisores 2016	85
All that glitters is not gold. A different cause for an "obscure colitis" A. Pineda, M. Soto, J. Villanueva and G. Navarro		

ARAN

www.revistareed.com

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CE 5678

Why anal cytology is not enough in a dysplasia screening program

Marco Silva, Rosa Coelho and Guilherme Macedo

Department of Gastroenterology. Centro Hospitalar de São João. Porto Medical School.
Porto, Portugal

Correspondence: Marco Silva

e-mail: marcocostasilva87@gmail.com

Key words: Anal cancer. Anoscopy. Screening.

Dear Editor,

In our previous study (1), we stated that anorectal cytology (ARC) should not be used as the sole method for anal dysplasia screening (ADS). We read with great interest the letter of Revollo et al. (2) and we would like to respond to some points.

Anal squamous cell carcinoma (ASCC) shares several similarities with its cervical counterpart, such as a causal association with human papillomavirus (HPV) and an intraepithelial cancer precursor (HSIL) stage that can be detected by ARC (3). It has been proposed that cytology-based ADS programs may similarly lead to a reduction in anal cancer incidence. However, such programs have been implemented in a limited number of situations, mostly in men who have sex with men (MSM) and/or with HIV (3). However, we agree with Revollo et al. that these screening programs should be offered to other high-risk populations, as in our study (1).

Most ADS programs use ARC as the preferred screening method, and patients with anal cytological abnormalities are referred for a diagnostic test such as standard or high-resolution anoscopy for histological assessment (4). Some programs only refer patients with HSIL for anoscopy guided biopsy, whereas other studies refer patients with any degree of cytological abnormality for biopsy. However, ARC is an imperfect screening method due to its limited sensitivity and specificity. Our results (1) show that

64% of patients with high-grade lesions on histological examination had lower grade lesions on cytological examination. Furthermore, four patients had a negative cytology test and if ARC was offered in these cases as the sole screening method, high-grade lesions would be missed. Considering the high rates of missed cases in high-risk populations that could really benefit from ADS, we think that ARC is inadequate, at least on its own. This technique should be paired with a direct visual modality, as other authors have suggested previously (5). Our results show that standard anoscopy could reduce the rate of missed lesions and should be offered to all high-risk groups.

References

1. Silva M, Peixoto A, Sarmiento JA, et al. Anal cytology, histopathology and anoscopy in an anal dysplasia screening program: is anal cytology enough? *Rev Esp Enferm Dig* 2018;110:109-14.
2. Revollo B, Videla S, Parés D. Anal intraepithelial neoplasia: how and to who perform a screening program? *Rev Esp Enferm Dig* 2018.
3. Jin F, Grulich AE, Poynten IM, et al. The performance of anal cytology as a screening test for anal HSILs in homosexual men. *Cancer Cytopathol* 2016;124:415-24. DOI: 10.1002/cncy.21702
4. Darragh TM, Winkler B. Screening for anal neoplasia: anal cytology - Sampling, processing and reporting. *Sex Health* 2012;9:556-61. DOI: 10.1071/SH12003
5. Leeds IL, Fang SH. Anal cancer and intraepithelial neoplasia screening: a review. *World J Gastrointest Surg* 2016;8:41-51. DOI: 10.4240/wjgs.v8.i1.41